In the BioHarmony Drug Report Database
Lasmiditan
Reyvow (lasmiditan) is a small molecule pharmaceutical. Lasmiditan was first approved as Reyvow on 2020-01-31. It is used to treat migraine with aura and migraine without aura in the USA. It is known to target 5-hydroxytryptamine receptor 1F. Reyvow’s patent is valid until 2037-12-05 (FDA).
Trade Name
|
Reyvow |
|---|---|
Common Name
|
lasmiditan |
ChEMBL ID
|
CHEMBL3039520 |
Indication
|
migraine with aura, migraine without aura |
Drug Class
|
Antimigraine (5-HT1 receptor agonists) |
Image (chem structure or protein)